These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 5762487)

  • 21. Antitumor action of cis-dichlorobis(methylamine)platinum(II).
    Gale GR; Rosenblum MG; Atkins LM; Walker EM; Smith AB; Meischen SJ
    J Natl Cancer Inst; 1973 Oct; 51(4):1227-34. PubMed ID: 4583374
    [No Abstract]   [Full Text] [Related]  

  • 22. Increased tolerance of leukemic mice to arabinosyl cytosine with schedule adjusted to circadian system.
    Haus E; Halberg F; Pauly JE; Cardoso S; Kühl JF; Sothern RB; Shiotsuka RN; Hwang DS
    Science; 1972 Jul; 177(4043):80-2. PubMed ID: 5041782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and antitumor and antiviral activities of 1- -D-arabinofuranosylpyrimidine 3',5'-cyclic phosphates.
    Long RA; Szekeres GL; Khwaja TA; Sidwell RW; Simon LN; Robins RK
    J Med Chem; 1972 Dec; 15(12):1215-8. PubMed ID: 4344168
    [No Abstract]   [Full Text] [Related]  

  • 24. EFFECT OF CHAIN LENGTH ON THE TEMPLATE ACTIVITY OF POLYRIBONUCLEOTIDES.
    JONES OW; TOWNSEND EE; SOBER HA; HEPPEL LA
    Biochemistry; 1964 Feb; 3():238-46. PubMed ID: 14163946
    [No Abstract]   [Full Text] [Related]  

  • 25. Increased lifespan of leukemic mice treated with drugs related to (-)-emetine.
    Jondorf WR; Abbott BJ; Greenberg NH; Mead JA
    Chemotherapy; 1971; 16(2):109-29. PubMed ID: 5120609
    [No Abstract]   [Full Text] [Related]  

  • 26. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.
    Neil GL; Moxley TE; Manak RC
    Cancer Res; 1970 Aug; 30(8):2166-72. PubMed ID: 4990003
    [No Abstract]   [Full Text] [Related]  

  • 27. Influence of antileukemic (L1210) treatment schedule on disposition of (minus)-emetine hydrochloride (NSC 33669) in normal and leukemic mice.
    Auletta AE; Gery AM; Mead JA
    Cancer Res; 1974 Jul; 34(7):1581-5. PubMed ID: 4833911
    [No Abstract]   [Full Text] [Related]  

  • 28. Protection against Toxoplasma gondii in mice immunized with Toxoplasma cell fractions, RNA and synthetic polyribonucleotides.
    Araujo FG; Remington JS
    Immunology; 1974 Oct; 27(4):711-21. PubMed ID: 4215743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.
    Venditti JM; Baratta MC; Greenberg NH; Abbott BJ; Kline I
    Cancer Chemother Rep; 1972 Aug; 56(4):483-92. PubMed ID: 5081591
    [No Abstract]   [Full Text] [Related]  

  • 30. Inhibition of in vitro protein synthesis by a carbocyclic puromycin analog.
    Vince R; Daluge S; Palm M
    Biochem Biophys Res Commun; 1972 Jan; 46(2):866-70. PubMed ID: 4550700
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of antileukemic agents employing advanced leukemia L1210 in mice. VII.
    Venditti JM; Sheldon DR; Goldin A
    Cancer Res; 1964 Jan; 24(1 Pt 1):145-210. PubMed ID: 5878215
    [No Abstract]   [Full Text] [Related]  

  • 32. Active immunotherapy.
    Mathé G
    Adv Cancer Res; 1971; 14():1-36. PubMed ID: 4330473
    [No Abstract]   [Full Text] [Related]  

  • 33. Antitumor activity of 1-acyloxymethyl derivatives of 5-fluorouracil against L1210 leukemia.
    Hoshi A; Inomata M; Kanzawa F; Iigo M; Kuretani K
    J Pharmacobiodyn; 1982 Mar; 5(3):208-12. PubMed ID: 7097489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of synthetic double-stranded ribonucleic acid (poly I:C) on SV40 viral oncogenesis and transplant tumor in hamsters.
    Larson VM; Panteleakis PN; Hilleman MR
    Proc Soc Exp Biol Med; 1970 Jan; 133(1):14-9. PubMed ID: 4312712
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of day of dosage omission on survival time in the regularly scheduled methotrexate (NSC-740) treatment of leukemia L1210.
    Straus MJ; Goldin A
    Cancer Chemother Rep; 1972 Feb; 56(1):25-30. PubMed ID: 5030806
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in L1210 leukemic mice.
    Kelly CJ; Gaudio L; Yesair DW; Schoenemann PT; Wodinsky I
    Cancer Treat Rep; 1978 Jul; 62(7):1025-32. PubMed ID: 80268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A new antitumor compound: hydroxy-9 ellipticin. Effect on mouse L 1210 leukemia].
    Le Pecq JB; Gosse C; Nguyen-Dat-Xuong ; Paoletti C
    C R Acad Hebd Seances Acad Sci D; 1973 Nov; 277(20):2289-91. PubMed ID: 4211276
    [No Abstract]   [Full Text] [Related]  

  • 38. Sparing action of uridine on the activity of arabinosylcytosine with normal and leukemic mice.
    Saslaw LD; Grindey GB; Kline I; Waravdekar VS
    Cancer Res; 1968 Jan; 28(1):11-20. PubMed ID: 5635365
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of 4,4'-diacetyl-diphenyl-urea-bis(guanylhydrazone) on leukemia L1210.
    Mihich E; Mulhern AI
    Cancer Res; 1968 Feb; 28(2):354-62. PubMed ID: 5641525
    [No Abstract]   [Full Text] [Related]  

  • 40. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia.
    Dombernowsky P; Nissen NI
    Acta Pathol Microbiol Scand A; 1973 Sep; 81(5):715-24. PubMed ID: 4771975
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.